Adam Laponis Sells 3,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer directly owned 137,031 shares of the company’s stock, valued at approximately $5,481,240. The trade was a 2.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The shares were sold at an average price of $35.26, for a total value of $96,541.88.
• On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total value of $173,454.48.

Twist Bioscience Trading Up 3.1%

TWST traded up $1.24 during trading hours on Thursday, reaching $41.27. 992,448 shares of the company’s stock traded hands, compared to its average volume of 1,403,489. The firm has a 50-day moving average price of $31.99 and a 200 day moving average price of $31.20. The firm has a market capitalization of $2.53 billion, a PE ratio of -31.50 and a beta of 2.19. The company has a quick ratio of 3.33, a current ratio of 3.64 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $55.33.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The business had revenue of $99.01 million for the quarter, compared to the consensus estimate of $97.40 million. Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new position in shares of Twist Bioscience in the 3rd quarter worth $28,000. Smartleaf Asset Management LLC grew its stake in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. National Bank of Canada FI bought a new position in Twist Bioscience in the third quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $97,000.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of research reports. TD Cowen raised their target price on shares of Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Stephens initiated coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective on the stock. Barclays upped their target price on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $44.67.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.